AC
RNTX

Annandale Capital’s Rein Therapeutics RNTX Stock Holding History

Annandale Capital’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20K Hold
15,026
– – ﹤0.01% 121
2025
Q4 		$17K Buy
+15,026
New +$20.7K ﹤0.01% 127

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Annandale Capital's RNTX Position: Q1 2026 in Review

Annandale Capital held its Rein Therapeutics (RNTX) position steady in Q1 2026 at 15,026 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #121.

Annandale Capital first reported a position in RNTX in Q4 2025 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Annandale Capital held 15,026 shares of Rein Therapeutics worth $20K as of Q1 2026.
  • Annandale Capital left its Rein Therapeutics share count unchanged in Q1 2026.
  • Rein Therapeutics made up ﹤0.01% of Annandale Capital's portfolio in Q1 2026, its #121 holding.
  • Annandale Capital first reported a position in Rein Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Annandale Capital's 13F filing for Q1 2026, filed 15 May 2026.